We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Point-of-Care Testing Evaluated for Early Coagulopathy Diagnosis

By LabMedica International staff writers
Posted on 09 Jun 2021
Print article
Image: The CoaguChek Pro II Coagulation Meter and CoaguChek PT Test Strips (Photo courtesy of Roche Diagnostics)
Image: The CoaguChek Pro II Coagulation Meter and CoaguChek PT Test Strips (Photo courtesy of Roche Diagnostics)
Hemorrhage and coagulopathy are particularly relevant complications and are often connected to injuries, surgical interventions, serious diseases, anticoagulant medication or pregnancy/delivery. Acute bleeding requires fast and targeted therapy and therefore, knowledge of the patient's potential to form a clot is crucial.

Treating bleeding complications, rapid hemostatic optimization (interventional, surgical, mechanical or medication) and targeted therapy are therapeutic goals and are therefore equivalent to those of coagulopathy treatment. The earlier a coagulopathy is diagnosed, the earlier a targeted therapy can be initiated. The international normalized ratio (INR) value is of particular importance for the diagnosis and therapy of coagulopathy.

Intensive Care Physicians at the University Hospital Frankfurt (Frankfurt, Germany) and their colleagues included in a study, one group that included hemorrhagic patients from the department of obstetrics (obstetric group = OG), and another group comprising patients admitted to the emergency department (emergency group = EG). The primary outcome measure was the difference between two INR results of one blood sample determined by point-of-care testing (POCT) and standard laboratory testing (SL).

After blood sampling, a drop of blood was applied immediately to the test stripe of the POCT device, CoaguChek Pro II (Roche Diagnostics GmbH, Mannheim, Germany). The CoaguChek Pro II is a portable device requiring an 8-μl sample volume. It measures the international normalized ratio (INR) based on an electrochemical reaction. Samples for SL analysis were sent to the central laboratory via a pneumatic dispatch system (EG) or personal-based transport (OG) for automated analysis with an ACL TOP 700 Hemostasis testing System, (Werfen GmbH, Munich, Germany) in combination with PT Re Combiplastin 2G reagents.

The team reported that INR results between POCT and SLA showed a high and significant correlation. POCT results were reported significantly more quickly (EG: 1.1 versus 39.6 minutes; OG: 2.0 versus 75 minutes) and required less time for analysis (EG: 0.3 versus 24.0 minutes; OG: 0.5 versus 45.0 minutes) compared to SLA. The time for transportation with the pneumatic tube was significantly shorter (8.0 versus 18.5 minutes) than with the personal-based transport system. The estimated blood loss was between 800 mL and 1300 mL.

The authors concluded that strip-based test systems may be suitable methods for the emergency diagnosis of hemorrhagic patients because their measurement results are available significantly more quickly and seem to support the use of point-of-care INR-devices to rule out pathological INR-values in bleeding patients. The test strip-based methods can be used as diagnostic elements in hemotherapy algorithms to implement fast and targeted hemotherapy that can positively impact the clinical outcomes of patients. The study was published on May 23, 2021 in the journal Practical Laboratory Medicine.

Related Links:
University Hospital Frankfurt
Roche Diagnostics
Werfen


New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
COVID-19 ELISA Kits
COVID-19 ELISA Kits
New
Automated Pipetting Solution
PIPETMAX
New
Laboratory Automation System
autioclart

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.